Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INV-9956 in metastatic castration-resistant prostate cancer (Phase I/II)
CTR20250269Phase 2Active
- Sponsor
- Guangdong Institute of Innovative Drug Translational Medicine
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INV-9956 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Guangdong Institute of Innovative Drug Translational Medicine. Started Aug 2025; status: active.
02
Drugs
INV-9956
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20250269.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250269.